BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has ...
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in ...
HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...
Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to ...
ISM6166 was nominated as a PCC as an oral, broad-spectrum pan‑KRAS ON/OFF inhibitor, designed to overcome resistance ...
VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor more potent than other KRAS G12D inhibitors in preclinical models VS-7375, when combined with cetuximab, demonstrated strong tumor ...
A previous study showed a confirmed objective response rate of 42.9% with the KRAS G12C inhibitor adagrasib in previously treated patients with NSCLC. In this phase III trial, median progression-free ...
Zacks Investment Research on MSN
TNGX stock hits record high on inking collaboration deal with ERAS
Shares of Tango Therapeutics TNGX surged 36.3% on Thursday to a record high after Erasca ERAS announced a clinical trial collaboration and supply agreement with the company. Under the agreement, the ...
Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to daraxonrasib in KRAS-mutated colorectal cancer cells – – Data support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results